Sun Pharmaceutical Industries Ltd has entered into an exclusive licensing agreement with LIB Therapeutics Inc to commercialise and manufacture lerodalcibep worldwide, excluding the United States and China, strengthening its presence in the global cardiovascular medicines market. Lerodalcibep, marketed as Lyrokaul in the European Union, is a once-monthly PCSK9 inhibitor designed to lower low-density lipoprotein cholesterol […]